

Jordan D Berlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1230971/publications.pdf>

Version: 2024-02-01

69
papers

12,161
citations

361413

20
h-index

114465

63
g-index

73
all docs

73
docs citations

73
times ranked

12702
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2335-2342.	27.0	9,850
2	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
3	Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. <i>Nature Medicine</i> , 2018, 24, 194-202.	30.7	303
4	Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 427-432.	2.3	95
5	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	3.7	94
6	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.	1.6	85
7	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷ Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
8	Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. <i>Clinical Cancer Research</i> , 2018, 24, 3829-3837.	7.0	69
9	Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. <i>Journal of Clinical Oncology</i> , 2017, 35, 3003-3003.	1.6	69
10	Phase II Study of Olaparib (AZD5363) After Standard Systemic Therapies for Disseminated Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 172-177.	3.7	58
11	Warfarin-5-FU Interaction – A Consecutive Case Series. <i>Pharmacotherapy</i> , 1999, 19, 1445-1449.	2.6	54
12	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.	1.6	53
13	Recent advances in the treatment of pancreatic cancer. <i>F1000Research</i> , 2020, 9, 131.	1.6	52
14	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 312-318.	0.6	51
15	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.	3.6	43
16	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.	2.0	38
17	A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 183-189.	6.4	38
18	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	3.7	30

#	ARTICLE	IF	CITATIONS
19	A phase I dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	6.4	29
20	Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. <i>Translational Oncology</i> , 2020, 13, 100828.	3.7	25
21	The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience. <i>Cancer Imaging</i> , 2018, 18, 47.	2.8	24
22	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
23	Frequent <i>BRAF</i> mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 284-289.	1.7	21
24	Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. <i>Clinical Colorectal Cancer</i> , 2020, 19, 137-140.	2.3	20
25	Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.	1.5	19
26	Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3108-3108.	1.6	19
27	A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2578.	1.6	19
28	Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 283.	3.7	19
29	Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 596-605.	2.6	18
30	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	7.0	18
31	Current Concepts in the Treatment of Resectable Pancreatic Cancer. <i>Current Oncology Reports</i> , 2018, 20, 39.	4.0	17
32	Harnessing the Immune System in Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 48.	3.0	17
33	Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results. <i>Investigational New Drugs</i> , 2018, 36, 442-450.	2.6	16
34	Targeting metastatic colorectal cancer – present and emerging treatment options. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 137.	0.7	14
35	In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 545-552.	2.8	14
36	Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. <i>Oncologist</i> , 2020, 25, 954-962.	3.7	14

#	ARTICLE	IF	CITATIONS
37	Phase II Trial of T138067, a Novel Microtubule Inhibitor, in Patients with Metastatic, Refractory Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 44-47.	2.3	13
38	First-in-Human PET Imaging and Estimated Radiation Dosimetry of I-[¹¹ C]-Glutamine in Patients with Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 36-43.	5.0	13
39	Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. <i>Investigational New Drugs</i> , 2019, 37, 315-322.	2.6	11
40	Ethics in Oncology: Consulting for the Investment Industry. <i>Journal of Clinical Oncology</i> , 2007, 25, 444-446.	1.6	10
41	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1555-1562.	7.0	10
42	Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. <i>American Journal of Surgical Pathology</i> , 2019, 43, 559-563.	3.7	10
43	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	2.0	9
44	Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. <i>Investigational New Drugs</i> , 2017, 35, 491-498.	2.6	7
45	A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2017, 35, 95-104.	2.6	6
46	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	2.3	6
47	PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. <i>American Journal of Clinical Pathology</i> , 2019, 152, 384-391.	0.7	5
48	External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. <i>JAMA Network Open</i> , 2022, 5, e2144170.	5.9	5
49	First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. <i>Investigational New Drugs</i> , 2022, , 1.	2.6	5
50	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 860-868.	2.6	4
51	A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. <i>Endocrine-Related Cancer</i> , 2021, 28, 203-212.	3.1	4
52	Racial disparity in taxane-induced neutropenia among cancer patients. <i>Cancer Medicine</i> , 2021, 10, 6767-6776.	2.8	4
53	Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. <i>Journal of Oncology and Cancer Research</i> , 2018, 2, 23-27.	0.1	4
54	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2131744.	5.9	4

#	ARTICLE	IF	CITATIONS
55	A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS375-TPS375.	1.6	4
56	Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. Journal of Gastrointestinal Cancer, 2019, 50, 709-715.	1.3	2
57	A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).. Journal of Clinical Oncology, 2021, 39, 93-93.	1.6	2
58	Uncommon Cancers of the Stomach. , 2006, , 352-366.		1
59	A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.. Journal of Clinical Oncology, 2021, 39, 363-363.	1.6	1
60	Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. JAMA Oncology, 2021, 7, 1060.	7.1	1
61	Peritoneal Carcinomatosis in Well-Differentiated Small-Intestinal Neuroendocrine Tumors with Mesenteric Tumor Deposits. Journal of Medical & Surgical Pathology, 2019, 4, 1-10.	0.2	1
62	Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the United States. American Journal of Cancer Research, 2020, 10, 3395-3405.	1.4	1
63	Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3559-3559.	1.6	1
64	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	3.7	0
65	Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.. Journal of Clinical Oncology, 2021, 39, 4109-4109.	1.6	0
66	Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surgical Oncology Clinics of North America, 2021, 30, 189-204.	1.5	0
67	Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, 578-578.	1.6	0
68	Current and future strategies for treating metastatic pancreatic cancer. Clinical Advances in Hematology and Oncology, 2004, 2, 510-2.	0.3	0
69	Efficacy and safety profile of antivascular endothelial growth factor receptor tyrosine kinase inhibitors (avRTKIs) in patients (Pts) with neuroendocrine tumors(NETs): A systematic review and meta-analysis (SRMA).. Journal of Clinical Oncology, 2022, 40, e16216-e16216.	1.6	0